

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTEC CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**VOLUNTARY ANNOUNCEMENT — LITIGATION**

This announcement is made by WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, “**WuXi AppTec**” or “**we**”) on a voluntary basis.

Reference is made to the Company’s announcement dated June 9, 2026 (the “**June 9 Announcement**”). As regard the designation by the United States Department of Defense (the “**DoD**”) of the Company as a “Chinese military company” (“**CMC**”) in the DoD’s updated Section 1260H list on June 8, 2026 (United States time), we stated in the June 9 Announcement that WuXi AppTec would take immediate actions to challenge and correct this erroneous designation.

On June 11, 2026 (United States time), the Company filed a complaint at the United States District Court for the District of Columbia (the “**Court**”) against the DoD. We strongly believe that the DoD’s decision to include WuXi AppTec as a CMC under Section 1260H is erroneous and unsupported by the facts or the legal criteria under the applicable statutes and case law. To protect the interests of our customers, partners, employees and shareholders of the Company, we have pleaded to the Court, among others, to (i) declare that the DoD’s designation of WuXi AppTec as a CMC is null, void and with no force and effect, (ii) vacate and set aside the designation of WuXi AppTec as a CMC and (iii) remove WuXi AppTec from the Section 1260H list.

Since our inception, WuXi AppTec has stood alongside thousands of pharmaceutical and life science companies with a simple but committed mission: to help bring life-saving and life-improving therapies and medicines to global patients in need. We remain fully committed to such mission and will continue to work with our partners and customers as usual. We also believe the facts will prevail.

The Company will keep the shareholders and potential investors of the Company informed of any further material developments in connection with the proceedings by way of further announcement(s) as and when appropriate.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, June 11, 2026

*As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.*

\* *For identification purposes only*